We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical Instrument Stocks' Earnings Preview: ISRG, IVTY, CHEK
Read MoreHide Full Article
The second-quarter 2016 earnings season has started on an encouraging note, with big banks reporting moderately fair results. However, growth trends are still dreary particularly due to the weaknesses in the energy and technology sector.
As per the latest Zacks Earnings Trend report, overall second-quarter earnings for S&P 500 companies are expected to be down 5.4% from the year-ago quarter on revenues that are estimated to decline 0.5%.
Total earnings for the energy sector are expected to be down 77.1% on lower revenues (down 25.7%). Excluding the Energy sector, earnings for the rest of the index are estimated to be down 2.1%.
The current week (Jul 18-22) will see releases from more than 299 companies, out of which 92 companies are S&P 500 members. Notably, Medical companies will start reporting this week. Medical is one of the seven sectors in the S&P 500 that is expected to report earnings growth in the second quarter.
Here is a sneak peek into three medical instruments companies that are lined up to report earnings on Jul 19.
After market close, Da-Vinci system maker Intuitive Surgical Inc. (ISRG - Free Report) is scheduled to report its quarterly numbers. Growing adoption of its robot-assisted surgical system among physicians for general surgery (hernia repair, colorectal) procedures and innovative product pipeline are key catalysts, in our view.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #4 (Sell) and Earnings ESP of 0.00%.
As per our model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to beat earnings. Simultaneously, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Invuity Inc is a medical technology company, which through its Intelligent Photonics technology platform enables the transmission, management and manipulation of light in surgical procedures.
Our proven model does not conclusively show that the company is likely to beat earnings, given the combination of Zacks Rank #4 and Earnings ESP of 0.00%.
We also note that Invuity's results compared unfavorably with the Zacks Consensus Estimate in the last four quarters, with an average miss of 91.15%.
Check-Cap Ltd. (CHEK - Free Report) is a medical diagnostics company, which develops ingestible imaging capsule that utilizes low-dose X-rays for Colorectal cancer screening.
Our proven model does not conclusively show that the company is likely to beat earnings, given the combination of Zacks Rank #2 and Earnings ESP of 0.00%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medical Instrument Stocks' Earnings Preview: ISRG, IVTY, CHEK
The second-quarter 2016 earnings season has started on an encouraging note, with big banks reporting moderately fair results. However, growth trends are still dreary particularly due to the weaknesses in the energy and technology sector.
As per the latest Zacks Earnings Trend report, overall second-quarter earnings for S&P 500 companies are expected to be down 5.4% from the year-ago quarter on revenues that are estimated to decline 0.5%.
Total earnings for the energy sector are expected to be down 77.1% on lower revenues (down 25.7%). Excluding the Energy sector, earnings for the rest of the index are estimated to be down 2.1%.
The current week (Jul 18-22) will see releases from more than 299 companies, out of which 92 companies are S&P 500 members. Notably, Medical companies will start reporting this week. Medical is one of the seven sectors in the S&P 500 that is expected to report earnings growth in the second quarter.
Here is a sneak peek into three medical instruments companies that are lined up to report earnings on Jul 19.
After market close, Da-Vinci system maker Intuitive Surgical Inc. (ISRG - Free Report) is scheduled to report its quarterly numbers. Growing adoption of its robot-assisted surgical system among physicians for general surgery (hernia repair, colorectal) procedures and innovative product pipeline are key catalysts, in our view.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #4 (Sell) and Earnings ESP of 0.00%.
INTUITIVE SURG Price and EPS Surprise
INTUITIVE SURG Price and EPS Surprise | INTUITIVE SURG Quote
As per our model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to beat earnings. Simultaneously, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
(Read more: Intuitive Surgical Q2 Earnings: What's in Store?)
Invuity Inc is a medical technology company, which through its Intelligent Photonics technology platform enables the transmission, management and manipulation of light in surgical procedures.
INVUITY INC Price and EPS Surprise
INVUITY INC Price and EPS Surprise | INVUITY INC Quote
Our proven model does not conclusively show that the company is likely to beat earnings, given the combination of Zacks Rank #4 and Earnings ESP of 0.00%.
We also note that Invuity's results compared unfavorably with the Zacks Consensus Estimate in the last four quarters, with an average miss of 91.15%.
CHECK CAP LTD Price and EPS Surprise
CHECK CAP LTD Price and EPS Surprise | CHECK CAP LTD Quote
Check-Cap Ltd. (CHEK - Free Report) is a medical diagnostics company, which develops ingestible imaging capsule that utilizes low-dose X-rays for Colorectal cancer screening.
Our proven model does not conclusively show that the company is likely to beat earnings, given the combination of Zacks Rank #2 and Earnings ESP of 0.00%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>